Serum Acylcarnitines May Predict Kidney Decline in Diabetes
A recent study found that serum levels of eleven acylcarnitines are linked to the decline in kidney function among patients with type 2 diabetes. The research suggests that these acylcarnitines can enhance the prediction of kidney function decline. The study was led by Vincenzo Trischitta and published in BMJ Open Diabetes Research & Care.
- ▪The study involved a discovery cohort of 575 patients and a validation cohort of 252 patients with type 2 diabetes.
- ▪Eleven acylcarnitines were independently associated with accelerated decline in estimated glomerular filtration rate (eGFR).
- ▪A multimarker score comprising six acylcarnitines improved the prediction of rapid eGFR decline.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:A prospective study showed that serum levels of eleven acylcarnitines were associated with the rate of decline in estimated glomerular filtration rate (eGFR) among patients with type 2 diabetes (T2D). Furthermore, combining six of these molecules into a score improved clinical risk prediction models for kidney function decline.METHODOLOGY:Although several metabolites have been found to affect the risk for kidney function decline in T2D, the role of circulating acylcarnitines — whose accumulation is considered a potential mechanism in kidney disease — has not been fully explored.Researchers conducted a prospective study to examine the association between baseline levels of 40 serum acylcarnitines and the decline in eGFR (mL/min/1.73 m2) in patients with T2D.They investigated two…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
